How should anti‑β2‑glycoprotein I antibody testing be ordered in the laboratory?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Order Anti-β2-Glycoprotein I Antibodies in the Laboratory

Order anti-β2-glycoprotein I antibodies as both IgG and IgM isotypes using either ELISA or automated solid-phase assays (chemiluminescence, flow cytometry, or multiplex systems) on plasma or serum samples. 1

Specific Ordering Instructions

Test Panel to Order

  • Anti-β2GPI IgG
  • Anti-β2GPI IgM
  • Both isotypes should be ordered simultaneously as part of comprehensive antiphospholipid antibody testing 1

Specimen Requirements

  • Sample type: Plasma or serum (both acceptable) 1
  • The test should be ordered as part of the complete antiphospholipid antibody panel, which includes:
    • Lupus anticoagulant (LAC)
    • Anticardiolipin antibodies (aCL) IgG/IgM
    • Anti-β2GPI IgG/IgM 1

Testing Platform Options

You can order this test using any of these validated platforms 1:

  • Traditional ELISA (enzyme-linked immunosorbent assay)
  • Automated systems including:
    • Chemiluminescence assays
    • Flow cytometry-based assays
    • Multiplex immunoassays
    • Magnetic microparticle-based systems

The 2025 ISTH guidance confirms that non-ELISA automated platforms are acceptable alternatives to traditional ELISA, as they offer better harmonization and reduced inter-laboratory variation 2.

Critical Timing Requirements

Positive results must be confirmed with repeat testing at least 12 weeks (≥12 weeks) after the initial test 1. This is mandatory for diagnosis—a single positive test is insufficient. Order the same panel again after this interval if initial testing is positive.

Interpretation Thresholds

Current Standards (2025)

The most recent 2025 ISTH guidance indicates that moderate and high titer thresholds are now defined as 40 Units and 80 Units respectively, with the previous 99th percentile cutoff approach abandoned for classification criteria 2. However, this applies specifically to classification criteria for research studies.

For Clinical Diagnosis

For routine clinical practice (not research classification), the laboratory should report results as:

  • Positive: Above the 99th percentile of normal controls 1
  • Results should ideally be interpreted using likelihood ratios with defined level intervals (low, moderate, high) 3

Important Caveats

What NOT to Order (Yet)

  • IgA anti-β2GPI: Not recommended for routine testing—clinical significance remains controversial 1
  • Anti-domain I β2GPI antibodies: Not part of standard diagnostic criteria, though emerging evidence suggests potential utility 2, 4
  • Other antiphospholipid antibodies: Not recommended for routine diagnosis 1

IgM Isotype Considerations

While IgG shows stronger association with thrombosis, IgM should still be ordered because:

  • Up to 10% of APS patients may have isolated IgM positivity 5
  • IgM has documented associations with pregnancy morbidity 1
  • Omitting IgM testing risks missing APS diagnoses 1

Standardization Issues

Be aware that significant inter-assay variability exists between commercial kits 1. The 2025 evidence suggests that using the 99th percentile cutoff from two different ELISA platforms may improve diagnostic accuracy when standardization is inadequate 6. Results should be reviewed collaboratively between clinical pathologists and clinicians 1.

Triple Positivity

Patients positive for all three tests (LAC, aCL, and anti-β2GPI) are at highest risk for thrombosis and pregnancy complications, making comprehensive testing essential 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.